hiv infections

Summary

Summary: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Top Publications

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  2. ncbi Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
  3. ncbi Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
  4. ncbi Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  5. ncbi Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
  6. ncbi Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA
    JAMA 304:321-33. 2010
  7. ncbi Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
    Reuben M Granich
    Department of HIV AIDS, WHO, Geneva, Switzerland
    Lancet 373:48-57. 2009
  8. ncbi Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
  9. ncbi HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
  10. ncbi Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010

Research Grants

Detail Information

Publications239 found, 100 shown here

  1. ncbi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  2. ncbi Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
    ..Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition...
  3. ncbi Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  4. ncbi Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  5. ncbi Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
    ..Taken together, the multiscale approach described here has uncovered multiprotein virus-host interactions that likely act in concert to facilitate the early steps of HIV-1 infection...
  6. ncbi Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA
    JAMA 304:321-33. 2010
    ....
  7. ncbi Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
    Reuben M Granich
    Department of HIV AIDS, WHO, Geneva, Switzerland
    Lancet 373:48-57. 2009
    ..We investigated a theoretical strategy of universal voluntary HIV testing and immediate treatment with ART, and examined the conditions under which the HIV epidemic could be driven towards elimination...
  8. ncbi Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  9. ncbi HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
    ..Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy...
  10. ncbi Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
    ..Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1...
  11. ncbi Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
    ..Understanding the molecular mechanisms of both Vpu-dependent and -independent mediated antagonism of BST-2 will be critical for therapeutic strategies that exploit this novel viral function...
  12. ncbi CD4+ count-guided interruption of antiretroviral treatment
    W M El-Sadr
    Division of Infectious Diseases, Harlem Hospital Center and Columbia University, New York, NY 10037, USA
    N Engl J Med 355:2283-96. 2006
    ..Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV)...
  13. ncbi CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr, Room 3509, Bethesda, MD 20892, USA
    J Exp Med 200:749-59. 2004
    ....
  14. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  15. ncbi Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial
    Robert C Bailey
    Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA
    Lancet 369:643-56. 2007
    ..Our aim was to determine whether male circumcision had a protective effect against HIV infection, and to assess safety and changes in sexual behaviour related to this intervention...
  16. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  17. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007
    ..The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence...
  18. ncbi Timing of initiation of antiretroviral drugs during tuberculosis therapy
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    N Engl J Med 362:697-706. 2010
    ..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
  19. ncbi Common genetic variation and the control of HIV-1 in humans
    Jacques Fellay
    Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    PLoS Genet 5:e1000791. 2009
    ..This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians...
  20. ncbi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
    ..This effort illustrates the power with which RNA interference and forward genetics can be used to expose the dependencies of human pathogens such as HIV, and in so doing identify potential targets for therapy...
  21. ncbi Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis
    Martin W G Brinkhof
    Division of International and Environmental Health, Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS ONE 4:e5790. 2009
    ..The retention of patients in antiretroviral therapy (ART) programmes is an important issue in resource-limited settings. Loss to follow up can be substantial, but it is unclear what the outcomes are in patients who are lost to programmes...
  22. ncbi High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men
    Hui Li
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS Pathog 6:e1000890. 2010
    ....
  23. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..Quantitative analysis of preseroconversion replication rates of HIV is useful for projecting the yield and predictive value of assays targeting primary HIV infection...
  24. ncbi Projections of global mortality and burden of disease from 2002 to 2030
    Colin D Mathers
    Evidence and Information for Policy Cluster, World Health Organization, Geneva, Switzerland
    PLoS Med 3:e442. 2006
    ..This paper describes the methods, assumptions, input data, and results...
  25. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  26. ncbi The immune response during acute HIV-1 infection: clues for vaccine development
    Andrew J McMichael
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Nat Rev Immunol 10:11-23. 2010
    ..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
  27. ncbi Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  28. ncbi Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes
    Margaret May
    Department of Social Medicine, University of Bristol, Bristol, UK
    Lancet 376:449-57. 2010
    ..We developed two prognostic models to estimate the probability of death in patients starting ART in sub-Saharan Africa...
  29. ncbi The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    Nilu Goonetilleke
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, England, UK
    J Exp Med 206:1253-72. 2009
    ..These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell-driven escape...
  30. ncbi Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial
    Ronald H Gray
    Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21215, USA
    Lancet 369:657-66. 2007
    ..Ecological and observational studies suggest that male circumcision reduces the risk of HIV acquisition in men. Our aim was to investigate the effect of male circumcision on HIV incidence in men...
  31. ncbi Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa
    Kristin L Dunkle
    Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
    Lancet 363:1415-21. 2004
    ..No study on women has yet assessed gender-based violence as a risk factor for HIV after adjustment for women's own high-risk behaviours, although these are known to be associated with experience of violence...
  32. ncbi Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009
    ..Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication...
  33. ncbi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
    ..This study highlights both the power and shortcomings of large scale loss-of-function screens in discovering host-pathogen interactions...
  34. ncbi Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings
    Bernard M Branson
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention proposed, Atlanta, GA 30333, USA
    MMWR Recomm Rep 55:1-17; quiz CE1-4. 2006
    ..Repeat screening in the third trimester is recommended in certain jurisdictions with elevated rates of HIV infection among pregnant women...
  35. ncbi HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  36. ncbi Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
    Richard E Haaland
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
    PLoS Pathog 5:e1000274. 2009
    ....
  37. ncbi Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  38. ncbi Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies
    Robert Hogg
    Lancet 372:293-9. 2008
    ..The average number of years remaining to be lived at age 20 years was about two-thirds of that in the general population in these countries...
  39. ncbi Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...
  40. ncbi Adherence to medication
    Lars Osterberg
    General Medicine Division, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    N Engl J Med 353:487-97. 2005
  41. ncbi Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care
    Marielle Bemelmans
    Medecins Sans Frontieres, Blantyre, Malawi
    Trop Med Int Health 15:1413-20. 2010
    ..To describe how district-wide access to HIV/AIDS care was achieved and maintained in Thyolo District, Malawi...
  42. ncbi Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis
    Edward J Mills
    Centre for International Health and Human Rights Studies, Toronto, Ontario, Canada
    JAMA 296:679-90. 2006
    ..Concerns about incomplete adherence among patients living in poverty have been an important consideration in expanding the access to antiretroviral therapy in sub-Saharan Africa...
  43. ncbi HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
    R K Heaton
    University of California, San Diego, USA
    Neurology 75:2087-96. 2010
    ....
  44. ncbi HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
    James Arthos
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 9:301-9. 2008
    ..On CD4+ T cells, engagement of alpha4beta7 by gp120 resulted in rapid activation of LFA-1, the central integrin involved in the establishment of virological synapses, which facilitate efficient cell-to-cell spreading of HIV-1...
  45. ncbi Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
    Nathalia Holt
    Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Nat Biotechnol 28:839-47. 2010
    ..The demonstration that a minority of CCR5(-/-) HSPCs can populate an infected animal with HIV-1-resistant, CCR5(-/-) progeny supports the use of ZFN-modified autologous hematopoietic stem cells as a clinical approach to treating HIV-1...
  46. ncbi Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis
    Suzanna Attia
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    AIDS 23:1397-404. 2009
    ..To synthesize the evidence on the risk of HIV transmission through unprotected sexual intercourse according to viral load and treatment with combination antiretroviral therapy (ART)...
  47. ncbi Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial
    P Mugyenyi
    MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
    Lancet 375:123-31. 2010
    ..This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa...
  48. ncbi Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  49. ncbi Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review
    Matthew P Fox
    Center for Global Health and Development, Boston University, Boston, MA 02118, USA
    Trop Med Int Health 15:1-15. 2010
    ..To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment...
  50. ncbi Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  51. ncbi Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response
    Beatrice Jacquelin
    Institut Pasteur, Unité de Régulation des Infections Rétrovirales, Paris, France
    J Clin Invest 119:3544-55. 2009
    ..In conclusion, SIV infection triggered a rapid and strong IFN-alpha response in vivo in both AGMs and RMs, with this response being efficiently controlled only in AGMs, possibly as a result of active regulatory mechanisms...
  52. ncbi Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review
    Roos E Barth
    University Medical Centre Utrecht, Department of Internal Medicine and Infectious Diseases, Netherlands
    Lancet Infect Dis 10:155-66. 2010
    ....
  53. ncbi HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    Nicolas Chomont
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal Saint Luc, Montreal, Quebec, Canada
    Nat Med 15:893-900. 2009
    ....
  54. ncbi Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
    Joel E Gallant
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    N Engl J Med 354:251-60. 2006
    ..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...
  55. ncbi Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    Jinyan Liu
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nature 457:87-91. 2009
    ..These findings have important implications for the development of next-generation T-cell-based vaccine candidates for HIV-1...
  56. ncbi Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry
    Melissa Alexander
    Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Rd, Atlanta, GA 30329, USA
    J Virol 84:4100-4. 2010
    ..Thus, HIV-1 transmission does not appear to select for viruses that can preferentially utilize low levels of entry receptors...
  57. ncbi Child mortality according to maternal and infant HIV status in Zimbabwe
    Edmore Marinda
    ZVITAMBO Project, Harare, Zimbabwe
    Pediatr Infect Dis J 26:519-26. 2007
    ..HIV causes substantial mortality among African children but there is limited data on how this is influenced by maternal or infant infection status and timing...
  58. ncbi Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes
    Birgitte B Simen
    454 Life Sciences, a Roche Company, Branford, Connecticut, USA
    J Infect Dis 199:693-701. 2009
    ..Minor (i.e., <20% prevalence) drug-resistant human immunodeficiency virus (HIV) variants may go undetected, yet be clinically important...
  59. ncbi The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
    ....
  60. ncbi Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
    Shabbar Jaffar
    Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 374:2080-9. 2009
    ..Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care...
  61. ncbi Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis
    Marie Louise Newell
    Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, London WC1N 1EH, UK
    Lancet 364:1236-43. 2004
    ..With individual data from seven randomised mother-to-child transmission (MTCT) intervention trials, we estimate mortality in African children born to HIV-infected mothers and analyse selected risk factors...
  62. ncbi Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e5683. 2009
    ..Greater V3 diversity was observed post-selection. This previously unreported degree of V3 loop sequence diversity has implications for viral pathogenesis, vaccine design, and the optimal use of HIV-1 CCR5 antagonists...
  63. ncbi Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
    Sharon Walmsley
    Toronto Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
    N Engl J Med 346:2039-46. 2002
    ....
  64. ncbi The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml
    Philippa J Easterbrook
    Department of HIV/GUM, Guy's, King's and St Thomas' School of Medicine, King's College Hospital, London, UK
    AIDS 16:1521-7. 2002
    ..This supports the adoption of a more pro-active approach to treatment intensification and the need for caution with structured treatment interruptions...
  65. ncbi Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study)
    Isabelle Pellegrin
    Department of Virology, Bordeaux University Hospital, Bordeaux, France
    AIDS 16:1331-40. 2002
    ..CONCLUSIONS: Our data confirm the association among individual pharmacokinetic parameters, genotype pattern and virological response to NFV-containing regimens...
  66. ncbi The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study
    Christian Laurent
    , France
    AIDS 16:1363-70. 2002
    ..Contrary to other recent studies in Africa, viral resistance rarely emerged...
  67. ncbi Impact of NNRTI compared to PI-based highly active antiretroviral therapy on CCR5 receptor expression, beta-chemokines and IL-16 secretion in HIV-1 infection
    C T Burton
    Department of Immunology, Imperial College of Science, Technology and Medicine, Chelsea and Westminster Hospital, London, UK
    Clin Exp Immunol 130:286-92. 2002
    ..Patients were genotyped for CCR5 Delta32 and the incidence of heterozygosity was lower than in the HIV-1 seronegative controls (3% compared to 19%)...
  68. ncbi Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne
    Pierre de Truchis
    Hôpital Garches, France
    J Acquir Immune Defic Syndr 31:178-82. 2002
    ..To evaluate the safety and efficacy of a protease inhibitor sparing, quadruple therapy (Combivir + abacavir + efavirenz) in antiretroviral treatment-naive HIV-1-infected adults...
  69. ncbi Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial
    Diana M Gibb
    Medical Research Counsel Clinical Trials Unit, London, UK
    Pediatr Infect Dis J 22:56-62. 2003
    ..Most studies of adherence to highly active antiretroviral therapy in children have been retrospective or cross-sectional. Factors relating to the caregiver, the child and the medication are all considered to be important for good adherence...
  70. ncbi Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy
    Ping Ye
    Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Clin Immunol 106:95-105. 2003
    ..We further predict that protease inhibitors have high levels of efficacy directly suppressing viral replication within the thymus, while reverse transcriptase inhibitors have low efficacy...
  71. ncbi Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes
    Elisabetta Chiesa
    Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy
    Antivir Ther 8:27-35. 2003
    ..92, P=0.004). CONCLUSIONS: Simplification is safe and effective, but it should be offered to patients with shorter treatment duration, and in good clinical and immunovirological conditions...
  72. ncbi Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling
    Franco Maggiolo
    Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy
    Antivir Ther 8:121-6. 2003
    ..Further studies should clarify whether this is true for other drugs of the nucleoside analogues class...
  73. ncbi Successful simplification of HAART in patients with acute primary HIV infection
    A Sinicco
    Department of Infectious Diseases, University of Turin, Italy
    J Biol Regul Homeost Agents 16:69-72. 2002
    ....
  74. ncbi Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California 92093-0672, USA
    J Infect Dis 185:1409-16. 2002
    ..Thus, despite prolonged maintenance of undetectable levels of plasma HIV-1 RNA, HIV-1 DNA remains detectable in PBMC of children and may be a useful marker of further virus suppression...
  75. ncbi Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression
    J Vaclavikova
    Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Flemingovo nam 2, 166 10 Prague, Czech Republic
    Acta Virol 49:29-36. 2005
    ..Efficient yet temporary suppression of viral replication was achieved by a lopinavir (LPV) treatment...
  76. ncbi Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection
    S A Stranford
    Department of Medicine, University of California, San Francisco, CA 94143; Blood Centers of the Pacific, San Francisco, CA 94118, USA
    Proc Natl Acad Sci U S A 98:597-602. 2001
    ....
  77. ncbi Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens
    J S Montaner
    British Columbia Centre for Excellence in HIV/AIDS, St Paul's Hospital, Vancouver, Canada
    AIDS 15:61-9. 2001
    ..Our data suggest that relying exclusively on historical, clinical and laboratory evidence may not be sufficient to rule out a possible antiviral response when multiple drug regimens are used in this heavily pretreated patient population...
  78. ncbi Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor
    B Rakotoambinina
    Service d'Immunologie Clinique, , , 75743 Paris Cedex 15, France
    J Acquir Immune Defic Syndr 27:443-9. 2001
    ..Hyperlipidemia is observed in the absence of lipodystrophy and depends on PI exposure...
  79. ncbi Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES)
    S H Lowe
    International Antiviral Therapy Evaluation Center IATEC, University of Amsterdam, Amsterdam, The Netherlands
    HIV Clin Trials 6:235-45. 2005
    ..To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen...
  80. ncbi Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz
    G M Lucas
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 15:1679-86. 2001
    ..CONCLUSIONS: In agreement with a recent clinical trial, use of initial EFV-based combination antiretroviral therapy was associated with higher rates of viral suppression than PI-based therapy in a clinical cohort...
  81. ncbi Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains
    J Goudsmit
    Department of Human Retrovirology, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    AIDS 15:2293-301. 2001
    ....
  82. ncbi Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy
    Ulrich R Hengge
    Department of Dermatology, Venerology and Allergology, University of Essen, Essen, Germany
    AIDS 16:151-60. 2002
    ..Substantial redistribution of lymphocytes occurs upon the initiation of highly active antiretroviral therapy (HAART) and immune-based HIV therapies...
  83. ncbi Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease
    Alan L Landay
    Department of Immunology Microbiology, Rush Medical College, Chicago, Illinois 60612, USA
    AIDS Res Hum Retroviruses 18:95-102. 2002
    ..The results of the study show that patients with extensive experience with NRTIs respond both virologically and immunologically during the first 48 weeks of therapy with a potent antiretroviral regimen...
  84. ncbi Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
    Tom Powles
    Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 16:531-6. 2002
    ..The CD4 T-cell count falls by 50% during chemotherapy and this will help to identify patients who require opportunistic infection prophylaxis during chemotherapy...
  85. ncbi Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads
    Michael A Kolber
    Division of Infectious Diseases, Department of Medicine, University of Miami School of Medicine, Miami, FL 33101, USA
    AIDS 16:537-42. 2002
    ....
  86. ncbi A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
    Calvin J Cohen
    Community Research Initiative of New England, Boston, MA 02215, USA
    AIDS 16:579-88. 2002
    ..003). CONCLUSION: Antiretroviral treatment guided prospectively by PRT led to the increased use of "active" antiretroviral agents and was associated with a significantly better virological response...
  87. ncbi Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
    Soo Aleman
    Division of Clinical Virology, Karolinska Institutet, Huddinge University Hospital, S-141 86 Stockholm, Sweden
    AIDS 16:1039-44. 2002
    ..This serial accumulation of mutations is likely to exhaust future drug options..
  88. ncbi Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial
    Sophie Matheron
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 8:163-71. 2003
    ..To compare the efficacy and safety of a triple nucleoside combination to a protease inhibitor-containing triple regimen as first-line antiretroviral therapy (ART) in HIV-1-infected patients...
  89. ncbi Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy
    Elena Chiappini
    Division of Paediatrics and Infectious Diseases, Department of Paediatrics, University of Florence, Florence, Italy
    J Med Virol 70:506-12. 2003
    ..The findings suggest, immunological recovery notwithstanding, virological failure is independent of drug-resistant mutations and consequent possible changes in viral fitness...
  90. ncbi Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy
    L Sarmati
    Department of Public Health, University of Rome Tor Vergata, Rome
    New Microbiol 27:95-8. 2004
    ..1-74.5%). The HIV strains of patients failing HAART showed a progressive impaired replication capacity. In patients failing HAART the impaired replication capacity of HIV strains could justify the persistence of an immune recovery...
  91. ncbi Factors associated with sustained virologic suppression in patients receiving antiretroviral therapy in an urban HIV care clinic
    Tania Purkayastha
    Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, AIDS Center Schiff 1, 111 East 210th Street, Bronx, NY 10467, USA
    AIDS Patient Care STDS 19:785-93. 2005
    ..Computerized query of the hospital information system proved to be a powerful tool for the identification of study patients in a real-world clinic environment...
  92. ncbi Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico
    M Escoto-Delgadillo
    Laboratory of Immunodeficiencies and Human Retrovirus, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara, Mexico
    HIV Med 6:403-9. 2005
    ....
  93. ncbi Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection
    C T Burton
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, UK
    Clin Exp Immunol 142:354-61. 2005
    ..The low numbers of responders and the transient nature of the anti-HIV-1 immune responses do not favour the auto-vaccination hypothesis...
  94. ncbi No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients
    Jade Ghosn
    Department of Infectious and Tropical Diseases, , Paris, France
    AIDS 19:1643-7. 2005
    ....
  95. ncbi A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load
    J A Arranz Caso
    Infectious Diseases Unit, Hospital Principe de Asturias, Madrid, Spain
    HIV Med 6:353-9. 2005
    ..To assess the antiviral efficacy and safety of switching from a protease inhibitor (PI) to nevirapine in patients with long-term HIV-1 RNA suppression on PI-containing regimens, and to assess its influence in the adherence to treatment...
  96. ncbi Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes
    Nonia Pariente
    , CSIC-UAM, Cantoblanco, Madrid, Spain
    J Med Virol 73:350-61. 2004
    ..5% of the patients. The results indicate successful suppression of HIV-1 under HAART for extended time periods, indistinguishable for patients in which evidence of virus evolution could or could not be documented...
  97. ncbi Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients
    Clotilde Allavena
    Service des Maladies Infectieuses et Tropicales/IFR26, , Nantes, France
    J Acquir Immune Defic Syndr 39:300-6. 2005
    ..CONCLUSION: The lopinavir/ritonavir-efavirenz combination is associated with a high rate of virologic response and should be compared with more classic NRTI-containing regimens in randomized and controlled clinical trials...
  98. ncbi Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
    Edwin DeJesus
    IDC Research Initiative, Altamonte Springs, FL, USA
    Clin Infect Dis 39:411-8. 2004
    ..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
  99. ncbi Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy
    J C Couto-Fernandez
    Laboratorio de AIDS e Imunologia Molecular, Departamento de Imunologia, Instituto Oswaldo Cruz FIOCRUZ, 21045 900 Rio de Janeiro, RJ, Brazil
    Mem Inst Oswaldo Cruz 100:73-8. 2005
    ..The maintenance of resistance genotyping programs for HIV-1 failing patients is important to the management of ARV therapies and to attempt and monitor the HIV-1 subtype prevalence in Brazil...
  100. ncbi Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    Margaret Johnson
    Royal Free Hospital, London, UK
    AIDS 19:685-94. 2005
    ....
  101. ncbi Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen
    Aylin Yilmaz
    Department of Infectious Diseases, Sahlgrenska University Hospital, , Sweden
    Scand J Infect Dis 36:823-8. 2004
    ..CSF concentrations of lopinavir were low, but probably sufficient to have a virological effect...

Research Grants172 found, 100 shown here

  1. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2002
    ..Results of the proposed study will guide the allocation of HIV prevention resources in establishing brief and effective HIV risk reduction counseling services for populations vulnerable to HIV infection. ..
  2. BIOPTERIN, CATECHOLAMINES, & NO IN REGULATING APOPTOSIS
    Robert Levine; Fiscal Year: 2002
    ..These studies may will reveal novel apoptotic regulatory mechanisms and provide new avenues for therapeutic approaches to promote neuronal survival and prevent debilitating neurological diseases, such as Parkinson's disease. ..
  3. Health of HIV-Infected Mothers after pMTCT, Botswana
    Shahin Lockman; Fiscal Year: 2007
    ..This already-existing cohort with access to ART provides a unique opportunity to answer questions that have significant public health implications with a relatively small investment of additional resources. ..
  4. Alcohol and HIV Risk Reduction in South Africa
    Seth Kalichman; Fiscal Year: 2006
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  5. Multilevel Alcohol-HIV/AIDS Prevention in South Africa
    Seth Kalichman; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  6. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2009
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  7. HIV Treatment Adherence Intervention for People with Poor Literacy Skills
    Seth C Kalichman; Fiscal Year: 2010
    ..Effective strategies for improving adherence in patients with poor health literacy must be tailored to achieve optimal adherence and therefore viral suppression. ..
  8. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2004
    ..If successful, the experimental intervention could be readily implemented as a community-based program by AIDS Service Organizations, health centers, and community-based Internet access providers. ..
  9. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  10. Gender Violence and HIV Risk Reduction in South Africa
    Leickness Simbayi; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,600 new HIV infections in South Africa each day...
  11. Training in Social Processes of HIV/AIDS
    Seth Kalichman; Fiscal Year: 2007
    ..Trainees will work with a community based AIDS service organization to conduct a field study that will serve as a rich training experience for them and will directly benefit the partner organization. ..
  12. HIV Treatment Adherence Intervention for People with Poor Literacy Skills
    Seth Kalichman; Fiscal Year: 2009
    ..Effective strategies for improving adherence in patients with poor health literacy must be tailored to achieve optimal adherence and therefore viral suppression. ..
  13. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2009
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  14. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2002
    ..Results of the proposed research will provide critical information about improving HIV treatment adherence with low-literacy populations that is needed prior to conducting larger and more expensive clinical trials. ..
  15. Multilevel Alcohol-HIV/AIDS Prevention in South Africa
    Seth C Kalichman; Fiscal Year: 2010
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  16. Alcohol-Related HIV Risks among South African Women
    Kathleen J Sikkema; Fiscal Year: 2010
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  17. Preventing HIV and other STDs among drug-involved women
    Nabila El Bassel; Fiscal Year: 2005
    ..The SWRD Program will be directed by Dr. Nabila El-Bassel and co-directed by Drs. Steven Schinke and Mary McKay, all CUSSW faculty with strong programs of federally funded research related to substance abuse and HIV. ..
  18. HIV/STI Risks Among Migrant Market Workers in Kazakhstan
    Nabila El Bassel; Fiscal Year: 2009
    ..The findings from this study will inform future prevention efforts to stem heterosexual transmission of HIV and STIs in Central Asia among male migrant workers. ..
  19. HIV/STI Prevention for Drug-Involved Couples
    Nabila El Bassel; Fiscal Year: 2007
    ..Dr. E1-Bassel, the Social Intervention Group Behavioral Studies at the NY State Psychiatric the study: Dr. Steinglass from the Ackerman Angeles, Dr. Sharp from St. Luke's Hospital tt the University of Buffalo. ..
  20. HIV/AIDS Risk Reduction for African American Couples
    Nabila El Bassel; Fiscal Year: 2007
    ..The findings will contribute significantly to an understanding of HIV/STD risk reduction among African American serodiscordant couples, a population at high risk of transmission. ..
  21. HIV/STD Risk Reduction For African American Couples
    Nabila El Bassel; Fiscal Year: 2006
    ..The findings will contribute significantly to the field of HIV/STI risk reduction by developing and testing an intervention with African American couples that can be offered to HIV clinics and CBOs. ..
  22. HIV/STI Risks Among Migrant Market Workers in Kazakhstan
    Nabila El Bassel; Fiscal Year: 2010
    ..The findings from this study will inform future prevention efforts to stem heterosexual transmission of HIV and STIs in Central Asia among male migrant workers. ..
  23. HIV RISK AND PARTNER VIOLENCE--MEN ON METHADONE
    Nabila El Bassel; Fiscal Year: 2002
    ..Data from the proposed study will help inform assessment, treatment and referral protocols to reduce partner violence and HIV-risk behaviors among men and women in MMTPs. ..
  24. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2002
    ....
  25. 2007 Case CFAR Annual Spring Conference
    Michael Lederman; Fiscal Year: 2007
    ..The Case CFAR is proactive in its efforts to ensure inclusion of minority and female researchers in all aspects of Conference planning and attendance. ..
  26. POL and Access Intervention to Reduce HIV Stigma among Service Providers in China
    Li Li; Fiscal Year: 2007
    ..The number of annual reported HIV infections in China has increased steadily...
  27. REGULATING MITF'S ACTIVATION OF OSTEOCLAST TARGET GENES
    KIM MANSKY; Fiscal Year: 2007
    ..By understanding how Mitf activates ostoeclast specific genes, drug targets may be suggested that will lead to therapies to control the differentiation and activation of osteoclasts. ..
  28. Topical Immune modulatory strategies to prevent HIV transmission
    Michael Lederman; Fiscal Year: 2007
    ..We expect that the results of these studies will provide insights into mechanisms of HIV acquisition across mucosal surfaces that will guide the further development of topical strategies to prevent HIV transmission. ..
  29. Comprehensive HIV Testing Strategies for Jails
    Curt Beckwith; Fiscal Year: 2007
    ..Dr. Beckwith will be mentored by Dr. Timothy P. Flanigan from Brown Medical School in Providence, Rl. Through this award, Dr. Beckwith aims to advance the delivery of HIV testing and prevention services to persons incarcerated in jail. ..
  30. HIV PREVENTION TRIAL UNIT
    David Metzger; Fiscal Year: 2006
    ..Thus, an additional aim of our group is to be active participants in three of the PTN science working groups-Microbicides, Behavioral Intervention, and Substance Related Transmission. ..
  31. Structure/Function Studies on Flavoproteins
    Irina Sevrioukova; Fiscal Year: 2007
    ..The study will explain the mechanisms of electron transfer and dithiol/disulfide oxidoreduction catalyzed by putidaredoxin reductase and will provide an insight into the mechanism and function of apoptosis inducing factor. ..
  32. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    BRUCE SCHACKMAN; Fiscal Year: 2009
    ....
  33. HIV Related Stigma among Service Providers in China
    Li Li; Fiscal Year: 2005
    ..These data will prepare the team to conduct a randomized controlled trial across different levels of health care providers in China. ..
  34. Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment Programs
    Bruce R Schackman; Fiscal Year: 2010
    ....
  35. ADULT AIDS CLINICAL TRIALS UNIT
    Michael Lederman; Fiscal Year: 2004
    ..The CWRU ACTU will also bring to the ACTG the expertise of its faculty in the laboratory monitoring of HIV disease through its Immunology Service Laboratory and other research laboratories within the institution. ..
  36. Efficacy of Drug-HIV counseling among IDU at Methadone clinics in Jakarta
    David S Metzger; Fiscal Year: 2010
    ..In settings such as Jakarta, data regarding the costs and benefits of integrated drug and risk counseling have critical public heath relevance. ..
  37. HIV/STD PREVENTION INTERVENTIONS FOR BLACK ADOLESCENTS
    JOHN JEMMOTT; Fiscal Year: 2003
    ..The results of this project will contribute to the development of effective HIV/STD risk-reduction programs for inner-city Black ..
  38. Genotypic and Phenotypic Characterization of Heterosexually Transmitted HIV-1
    Manish Sagar; Fiscal Year: 2010
    ..We will explore the biological relevance of observed differences in these phenotypic properties to develop potential biological models for selection during HIV-1 transmission. ..